Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Gilead Sciences Inc., consolidated cash flow statement (quarterly data)

US$ in millions

3 months ended:	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Net income (loss)	2,183)	3,052)	1,960)	1,315)	1,783)	1,253)	1,614)	(4,170)	1,417)	2,172)	1,039)	985)	1,633)	1,786)	1,135)	12)	376)	2,586)	1,517)	1,722)
Depreciation expense	90)	90)	93)	97)	95)	94)	98)	94)	91)	86)	83)	94)	83)	80)	80)	80)	90)	82)	79)	78)
Amortization expense	597)	596)	598)	599)	598)	596)	596)	596)	597)	598)	598)	546)	445)	445)	445)	445)	445)	441)	440)	395)
Stock-based compensation expense	230)	230)	225)	209)	222)	216)	210)	187)	201)	202)	198)	165)	174)	168)	165)	130)	159)	171)	166)	139)
Deferred income taxes	(122)	659)	(178)	(199)	(379)	(576)	(166)	(723)	(370)	(68)	(221)	(303)	(338)	(270)	(293)	(651)	(359)	240)	(68)	71)
Net (gain) loss from equity securities	(253)	(482)	(142)	426)	126)	(257)	391)	14)	(189)	169)	(69)	256)	61)	197)	303)	96)	(57)	142)	174)	351)
Acquired in-process research and development expenses	539)	170)	62)	253)	(11)	505)	38)	4,131)	347)	91)	236)	481)	158)	448)	330)	8)	—)	19)	96)	62)
In-process research and development impairments	400)	—)	190)	—)	—)	1,750)	—)	2,430)	50)	—)	—)	—)	—)	—)	—)	2,700)	—)	—)	—)	—)
Other, net	267)	90)	33)	90)	58)	86)	90)	119)	568)	54)	143)	62)	234)	126)	238)	182)	737)	25)	375)	201)
Accounts receivable, net	179)	(333)	(292)	79)	72)	162)	(29)	(66)	220)	(612)	(86)	635)	(281)	(372)	(452)	699)	41)	(422)	(281)	975)
Inventories	(123)	(515)	(175)	(223)	(226)	(85)	(70)	(45)	(307)	(82)	(226)	(227)	(276)	(95)	8)	53)	35)	70)	(25)	(69)
Prepaid expenses and other	(36)	(368)	81)	12)	(146)	(57)	(19)	(37)	(32)	5)	40)	26)	(65)	12)	(27)	(54)	(25)	(15)	6)	(8)
Accounts payable	(95)	230)	(162)	(105)	(58)	359)	(83)	72)	(43)	(29)	(3)	(272)	264)	66)	(13)	(91)	124)	(20)	31)	(253)
Income tax assets and liabilities, net	(134)	(122)	(1,300)	(552)	536)	111)	(1,171)	(208)	(698)	(881)	(28)	(161)	119)	108)	(479)	(112)	99)	72)	(219)	(316)
Accrued and other liabilities	(395)	811)	(166)	(244)	305)	152)	(174)	(175)	317)	50)	634)	(543)	356)	164)	362)	(1,657)	1,540)	(138)	25)	(738)
Changes in operating assets and liabilities	(604)	(297)	(2,014)	(1,033)	483)	642)	(1,546)	(459)	(543)	(1,549)	331)	(542)	117)	(117)	(601)	(1,162)	1,814)	(453)	(463)	(409)
Adjustments to reconcile net income (loss) to net cash provided by operating activities	1,144)	1,056)	(1,133)	442)	1,192)	3,056)	(289)	6,389)	752)	(417)	1,299)	759)	934)	1,077)	667)	1,828)	2,829)	667)	799)	888)
Net cash provided by operating activities	3,327)	4,108)	827)	1,757)	2,975)	4,309)	1,325)	2,219)	2,169)	1,755)	2,338)	1,744)	2,567)	2,863)	1,802)	1,840)	3,205)	3,253)	2,316)	2,610)
Purchases of marketable debt securities	(1,382)	(270)	(2,287)	—)	—)	—)	—)	(244)	(456)	(369)	(578)	(527)	(372)	(308)	(477)	(613)	(626)	(813)	(1,147)	(931)
Proceeds from sales of marketable debt securities	340)	219)	295)	—)	—)	—)	—)	2,265)	98)	95)	150)	167)	42)	47)	204)	119)	224)	255)	191)	60)
Proceeds from maturities of marketable debt securities	23)	17)	15)	—)	—)	—)	—)	327)	349)	266)	395)	324)	358)	277)	449)	506)	372)	558)	631)	619)
Acquisitions, including in-process research and development, net of cash acquired	(609)	(167)	(21)	(273)	(75)	(570)	(152)	(4,043)	(279)	(79)	(243)	(551)	(218)	(448)	(324)	(807)	(1)	(54)	(92)	(1,255)
Purchases of equity securities	(14)	(82)	(21)	(16)	(39)	(9)	(34)	(410)	(224)	(26)	(67)	(125)	(6)	(122)	(16)	(28)	(48)	(31)	(22)	(279)
Purchases of property, plant and equipment	(205)	(147)	(107)	(104)	(147)	(141)	(130)	(105)	(215)	(122)	(139)	(109)	(181)	(157)	(143)	(247)	(156)	(139)	(119)	(165)
Other investing activities, net	12)	3)	10)	(22)	36)	10)	9)	3)	—)	6)	(1)	(5)	2)	(2)	(1)	—)	(43)	(10)	(19)	(91)
Net cash used in investing activities	(1,835)	(427)	(2,116)	(415)	(225)	(710)	(307)	(2,207)	(727)	(229)	(483)	(826)	(375)	(713)	(308)	(1,070)	(278)	(234)	(577)	(2,042)
Proceeds from debt financing, net of issuance costs	—)	—)	—)	—)	3,464)	—)	—)	—)	1)	1,979)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Proceeds from issuances of common stock	32)	97)	27)	252)	173)	98)	5)	146)	26)	83)	26)	97)	176)	36)	3)	94)	12)	57)	12)	88)
Repurchases of common stock under repurchase programs	(230)	(435)	(527)	(730)	(350)	(300)	(100)	(400)	(150)	(300)	(150)	(400)	(792)	(180)	(72)	(352)	(49)	(145)	(43)	(309)
Repayments of debt and other obligations	(8)	(9)	(9)	(1,762)	(7)	(112)	(1,851)	—)	—)	(2,250)	—)	—)	—)	(1,000)	—)	(500)	(1,000)	(2,500)	—)	(1,250)
Payments of dividends	(994)	(1,005)	(994)	(1,010)	(973)	(983)	(972)	(990)	(943)	(953)	(944)	(969)	(915)	(929)	(920)	(945)	(894)	(900)	(894)	(917)
Other financing activities, net	(63)	(137)	(64)	(176)	(47)	(82)	(35)	(117)	(33)	(78)	(33)	(134)	(23)	(45)	(14)	(91)	(11)	(39)	(6)	(89)
Net cash used in financing activities	(1,263)	(1,489)	(1,567)	(3,426)	2,260)	(1,379)	(2,953)	(1,361)	(1,099)	(1,519)	(1,101)	(1,406)	(1,554)	(2,118)	(1,003)	(1,794)	(1,942)	(3,527)	(931)	(2,477)
Effect of exchange rate changes on cash and cash equivalents	4)	(5)	73)	19)	(55)	44)	(11)	(18)	37)	(6)	14)	12)	75)	(72)	(48)	(18)	(9)	(23)	20)	(23)
Net change in cash and cash equivalents	233)	2,187)	(2,783)	(2,065)	4,955)	2,264)	(1,946)	(1,367)	380)	1)	768)	(476)	713)	(40)	443)	(1,042)	976)	(531)	828)	(1,932)

The financial information reveals fluctuating cash flows over the observed period, spanning from March 2021 to December 2025. Operating activities generally provide a net cash inflow, though the magnitude varies considerably. Investing activities consistently represent a net cash outflow, primarily driven by acquisitions and purchases of marketable securities. Financing activities demonstrate a complex pattern, shifting between net cash inflows and outflows, significantly influenced by debt activity, stock repurchases, and dividend payments.

Net Income and Operating Cash Flow: Net income exhibits substantial volatility. A peak is observed in September 2021, followed by a significant decline in December 2021. Subsequent periods show recovery, but with further fluctuations, including a substantial net loss in March 2024. Despite these income variations, net cash provided by operating activities remains consistently positive throughout the period, though it mirrors the income trends to some extent. The adjustments to reconcile net income to net cash from operations, particularly deferred income taxes and net gains/losses from equity securities, contribute significantly to the differences between net income and operating cash flow. A notable increase in adjustments is seen in March 2024, coinciding with the net loss.
Investing Activities: Investing activities consistently consume cash. Acquisitions, including in-process research and development, represent a major outflow, with a particularly large expenditure in March 2024. Purchases of marketable debt securities and equity securities also contribute to the cash outflow. While proceeds from sales and maturities of debt securities provide some offset, they are insufficient to reverse the overall negative cash flow from investing. The pattern suggests a strategic focus on growth through acquisitions and investments, despite the associated cash drain.
Financing Activities: Financing activities demonstrate a more dynamic pattern. Repurchases of common stock and dividend payments consistently represent significant cash outflows. Debt financing provides inflows at times, but is often offset by repayments. A substantial inflow from proceeds from debt financing is observed in December 2024. The net effect of these activities results in periods of both net cash inflow and outflow, indicating active management of the capital structure. The large outflow in financing activities during the period ending June 2025 is notable.
Working Capital: Changes in operating assets and liabilities show considerable fluctuation. Accounts receivable demonstrates variability, with significant decreases in some quarters and increases in others. Inventory levels also fluctuate, generally showing decreases. Accounts payable and accrued liabilities exhibit similar patterns of change. These working capital movements contribute to the adjustments made in reconciling net income to operating cash flow.
Key Trends: From 2021 to 2023, the company generally maintained positive cash flow from operations and strategically utilized financing activities. However, 2024 and early 2025 show a marked shift, with a significant net loss in March 2024, increased investing outflows (particularly related to acquisitions), and a substantial net cash outflow from financing activities. This suggests a period of increased investment and potentially restructuring, funded by debt and potentially impacting overall cash reserves.

Overall, the cash flow statement reflects a company engaged in active investment, strategic acquisitions, and a dynamic capital structure management. The recent periods (2024-2025) indicate a potential shift in strategy or a period of significant investment, requiring close monitoring of future performance.

AI Ask an analyst for more

Download chart

Gilead Sciences Inc. (NASDAQ:GILD)

Cash Flow Statement Quarterly Data

Cash Flow Statement
Quarterly Data